Cost-Effectiveness of “Golden Mustard” for Treating Vitamin A Deficiency in India

Jeffrey Chow1, Eili Y. Klein2,3, Ramanan Laxminarayan3,4*

1 School of Forestry and Environmental Studies, Yale University, New Haven, Connecticut, United States of America, 2 Department of Ecology and Evolutionary Biology, Princeton University, Princeton, New Jersey, United States of America, 3 Center for Disease Dynamics, Economics, and Policy, Washington, D.C., United States of America, 4 Princeton Environmental Institute, Princeton University, Princeton, New Jersey, United States of America

Abstract

Background: Vitamin A deficiency (VAD) is an important nutritional problem in India, resulting in an increased risk of severe morbidity and mortality. Periodic, high-dose vitamin A supplementation is the WHO-recommended method to prevent VAD, since a single dose can compensate for reduced dietary intake or increased need over a period of several months. However, in India only 34 percent of targeted children currently receive the two doses per year, and new strategies are urgently needed.

Methodology: Recent advancements in biotechnology permit alternative strategies for increasing the vitamin A content of common foods. Mustard (Brassica juncea), which is consumed widely in the form of oil by VAD populations, can be genetically modified to express high levels of beta-carotene, a precursor to vitamin A. Using estimates for consumption, we compare predicted costs and benefits of genetically modified (GM) fortification of mustard seed with high-dose vitamin A supplementation and industrial fortification of mustard oil during processing to alleviate VAD by calculating the avertable health burden in terms of disability-adjusted life years (DALY).

Principal Findings: We found that all three interventions potentially avert significant numbers of DALYs and deaths. Expanding vitamin A supplementation to all areas was the least costly intervention, at $23–$50 per DALY averted and $1,000–$6,100 per death averted, though cost-effectiveness varied with prevailing health subcenter coverage. GM fortification could avert 5 million–6 million more DALYs and 8,000–46,000 more deaths, mainly because it would benefit the entire population and not just children. However, the costs associated with GM fortification were nearly five times those of supplementation. Industrial fortification was dominated by both GM fortification and supplementation. The cost-effectiveness ratio of each intervention decreased with the prevalence of VAD and was sensitive to the efficacy rate of averted mortality.

Conclusions: Although supplementation is the least costly intervention, our findings also indicate that GM fortification could reduce the VAD disease burden to a substantially greater degree because of its wider reach. Given the difficulties in expanding supplementation to areas without health subcenters, GM fortification of mustard seed is an attractive alternative, and further exploration of this technology is warranted.

Introduction

Vitamin A deficiency (VAD) is an important nutritional problem in large parts of the developing world, affecting as many as 130 million children [1]. VAD results in an increased risk of severe morbidity and mortality due to anaemia and depressed resistance to infectious disease and is responsible for more than a million child deaths annually. The most apparent result of VAD is clinical eye symptoms due to xerophthalmia (a destructive dryness of the conjunctival epithelium, manifested in early stages by deposits in the conjunctiva known as Bitot’s spots), making it the leading cause of preventable childhood blindness in developing countries [1]. VAD also affects many women in poor countries, specifically causing night blindness, anaemia, and increased maternal morbidity and mortality during pregnancy and lactation.

Though the incidence of clinical VAD in India has declined significantly over the past few decades, the country has the greatest number (more than 35 million) and the greatest percentage of VAD children in the world [1], and VAD persists as a public health problem, especially in rural areas [2,3]. The overall prevalence of xerophthalmia among children is 1.7 percent [4], and approximately 0.8 percent of all children suffer from Bitot’s spots [5], but state and local rates can vary significantly (Figure 1). Subclinical VAD is even more prevalent, with recent estimates (31–57 percent of children under six) placing India among the highest in the world [1,4]. VAD also afflicts more than 12 percent of the population with low vitamin A levels, increasing the risk of mortality and morbidity in children and adults [1,4].
of all mothers nationwide [6], and 19 states have night blindness rates for pregnant women exceeding 5 percent [7].

VAD occurs primarily in the lower socioeconomic strata of poor countries, among people with limited food choices and diets predominated by less nutritious staple foods [8]. Strategies for addressing VAD have traditionally fallen into three main categories: supplementation, food fortification, and diet and behavior modification. Recent advancements in biotechnology have created an additional avenue for addressing VAD: biofortification—using genetic recombinant technology to develop genetically modified (GM) fortified products with enhanced expression of provitamin A carotenoids, such as vitamin A–enhanced rice, or “golden rice” [9]. It has been suggested that introducing golden rice in India could decrease VAD prevalence by as much as 59 percent [10], but people in some regions in India with a high prevalence of VAD traditionally do not consume significant amounts of rice. Moreover, the unconventional color of golden rice may discourage its consumption, and poor people may not consume enough fat to facilitate biological absorption of the carotenoids [11–13].

However, rice is not the only crop that has been modified to express high levels of beta-carotene; mustard (Brassica juncea) can be modified to express significantly higher levels of beta-carotene, as much as 600 μg/g [14,15]. In addition, beta-carotene levels are conserved when the mustard seeds are pressed into oil, which is widely consumed in many parts of India with a high prevalence of VAD, even by lower socioeconomic groups (see Supplementary Notes S1 and Supplementary Figures S1 and S2 for more information on mustard oil consumption in India). Only a few drops of the transgenic oil would satisfy the recommended daily allowance for vitamin A intake.

Periodic, high-dose vitamin A supplementation is the most widely used public health approach to preventing deficiency [16]. A single dose can provide a reserve of vitamin A to compensate for reduced dietary intake or increased need over a period of several months. However, in India the percentage of targeted children currently receiving two doses per year, distributed by the Reproductive and Child Health program, is reported to be approximately 30 percent [6,17], and new strategies are urgently needed. We examined the costs and health benefits of GM fortification of mustard oil in India. Although several recent studies have examined the possible effect of different genetically modified foods [10,13,18,19], none have compared the costs and outcomes of different approaches. Thus, in our cost-benefit analysis we include three population-based strategies to improve the vitamin A status of at-risk groups: high-dose vitamin A supplementation for preschoolers (ages 1 to 4); industrial fortification of mustard oil during processing; and GM fortification of mustard oil.

Our analysis focused on states in India that consume mustard oil in significant quantities and that have been shown to have a high prevalence of VAD. These include states where mustard is grown and consumed (Uttar Pradesh, Bihar, Assam, West Bengal, Madhya Pradesh, Rajasthan, Jharkhand, Orissa, Haryana, Gujarat, Punjab, Jammu and Kashmir, and Himachal Pradesh) and states where mustard is not grown but consumed (Manipur, Nagaland, and Tripura). We also emphasized those states where Bitot’s spots prevalence rates indicate that VAD is a public health problem: Uttar Pradesh, Bihar, Assam, West Bengal, Madhya Pradesh, Rajasthan, Jharkhand, and Tripura. We also emphasized those states where Bitot’s spots prevalence rates indicate that VAD is a public health problem: Uttar Pradesh, Bihar, Assam, West Bengal, Madhya Pradesh, Rajasthan, Jharkhand, and Tripura. These analyses focused on the rural areas of these states, where the vast majority of the population lives. Information on prevalence rates for urban areas is not as comprehensively available as those for rural areas,
where surveyors such as the National Nutrition Monitoring Bureau (NNMB) focus their efforts. Hence, we included a subset of states with urban prevalence estimates (Uttar Pradesh, Bihar, West Bengal, Madhya Pradesh, Jharkhand, Jammu and Kashmir) as well as the urban populations in two well-studied metropolitan areas, Chandigarh and Delhi, for urban-specific analyses. The implementation of health initiatives in India is typically the responsibility of individual states, and it would make little sense for states with low prevalence of VAD or negligible consumption of mustard oil to participate in vitamin A GM fortification efforts.

Methods

We examined alternative population-based strategies to alleviate VAD by calculating the avertable health burden in terms of disability-adjusted life years (DALY) as well as avertable deaths and by comparing incremental cost-effectiveness ratios (ICER) in terms of unit cost per both DALY and death avertered. DALYs are a measure of healthy life years—the sum of the present value of years of future lifetime lost through premature mortality plus the present value of years of future lifetime, adjusted for the average severity of the mental or physical disability caused by a disease or injury [20]. The DALY metric allows comparisons of alternative health strategies using a single index that combines information about mortality and morbidity and has been widely used in similar analyses [10,13,18,19].

We also calculated the effect of a specific intervention as the number of DALYs averted, defined as

\[
\text{DALYs averted} = \text{YLL averted} + \text{YLD temp, averted} + \text{YLD perm, averted} \tag{1}
\]

where \(\text{YLL averted}\) is the number of discounted life-years averted, and \(\text{YLD temp, averted}\) and \(\text{YLD perm, averted}\) are years of life with temporary and permanent disability averted, respectively, due to morbidity. To account for varying disease levels among the different target groups affected by the three strategies, \(\text{YLL averted, YLD temp, averted, and YLD perm, averted}\) are defined as follows:

\[
\text{YLL averted} = \sum_j T_j M_j^{averted} (1 - e^{-rL_j})(1/r) \tag{2}
\]

\[
\text{YLD temp, averted} = \sum_k \sum_j T_j I_j^{averted} D_k (1 - e^{-rL_j})(1/r) \tag{3}
\]

\[
\text{YLD perm, averted} = \sum_j \sum_l T_j I_j^{averted} D_l (1 - e^{-rL_j})(1/r) \tag{4}
\]

where \(T_j\) is the total number of people in the target group \(j\), \(M_j^{averted}\) is the reduction in the mortality rate of the target group due to the intervention and \(L_j\) is the average remaining life expectancy. \(I_j^{averted}\) and \(D_{kl}\) are reductions in the morbidity rates of temporary and permanent sequelae \(k\) and \(l\), respectively. \(D_k\) and \(D_l\) are the corresponding disability weights. The parameter \(t\) is the duration of the intervention, and \(r\) is the discount rate of future life years, which is the standard 3 percent rate used in DALY calculations as recommended by the World Bank [21].

We considered the effect of an intervention over a 20-year time frame. We assumed that the reduction of temporary sequelae, such as Bitot’s spots and night blindness, is impermanent, lasting only as long as the duration of the intervention. For example, an individual receiving vitamin A supplementation up to an age of 4 years could still develop Bitot’s spots at age 5, at which point the intervention would have ceased for that individual. However, permanent sequelae, such as blindness, are averted for the lifetime of the treated individual, since the intervention allows an individual to pass through the most high-risk period for the onset of blindness unscathed. Second, we assumed that individuals whose lives have been saved by the intervention go on to live for their remaining life expectancy. Finally, we assumed that an intervention lasting less than two years for a cohort of preschool children would reduce neither the mortality rate nor permanent sequelae among that cohort, since a single dose compensates for reduced intake for only several months. Thus, we conservatively assume that premature cessation of supplementation would put a child at full risk of VAD morbidity and mortality.

We evaluated the cost-effectiveness of a particular intervention relative to other possible interventions according to the ratio of its total cost to its total effectiveness over the entire 20-year time frame, assuming that the program is already running at full capacity. Costs were discounted at a 3 percent annual rate. Effectiveness is in terms of avertered deaths or avertered DALYs. Because we lacked baseline data by state on current supplementation coverage, and anecdotal accounts suggest it is lower than reported [22], we assumed that VAD data were collected in the absence of an intervention. Hence, our baseline assumes that little or no intervention currently exists, but we account for possible underlying supplementation coverage by applying a range of effectiveness rates. All ICERs express the incremental impact of each non-dominated intervention. A larger cost-effectiveness ratio indicates a higher cost per unit of health gained. Prior to the calculation of ICERs, we excluded interventions that are strictly dominated—that is, interventions that are both less effective and more costly than at least one other strategy. In addition to calculating the number ofDALYs averted for each intervention, we also calculated ICERs for deaths averted. Lastly, we attributed a monetary value to a DALY to calculate internal rates of return (IRR). The monetary value chosen was annual per capita income for the year 2003–2004 [23]. As with similar analyses [13], the IRR estimates generated should be interpreted carefully. The goal of this approach was to estimate a useful metric for economic analysis rather than to predict rates of return on investment. These metrics offer an index, scaled to the average local living standard, by which the comparative value of an intervention can be judged.

Finally, GM-fortified mustard is still in the research and development stage. Hence, in this ex ante framework, parameters such as program costs and the reductions in mortality and morbidity rates are not yet known and must be estimated based on assumptions about health services, agriculture, and food production and delivery systems in India. All assumptions are based on the best biomedical research available, drawn from published studies as well as interviews with experts in VAD and mustard production and consumption in India.

Data

Our analysis used state-specific data where possible to estimate state-specific mustard oil consumption among young children and women of reproductive age, as well as rates of effectiveness in reducing morbidity and mortality associated with vitamin A deficiency. We calculated all results in 2005 U.S. dollars, using the exchange rate of Rs. 40 = US$1.

Strategies

We analyzed three interventions: (1) high-dose vitamin A supplementation; (2) industrial fortification of mustard oil; and (3) GM fortification of mustard oil with genetically modified mustard seed. Averted DALYs were calculated based on (1) avoided
Because we lacked baseline data on the effectiveness of vitamin A supplementation to reduce morbidity specific to our study areas, we used a range of values reported in the literature (Table 1). Costs were calculated by multiplying the number of preschool children by per capita costs (Table 2). The extent of mortality reduction due to vitamin A supplementation is somewhat contentious, ranging from estimates as high as 23 percent [35,36] to insignificant [24,37,38]. A recent study from northern India found reductions in mortality of about 4 percent [39]. Thus, we assumed a range of 4 to 23 percent. Avoided mortality was converted to DALYs by multiplying the number of deaths averted by life expectancy. The National Prophylaxis Programme for Prevention of Blindness due to Vitamin A Deficiency in India is implemented through the existing Primary Health Care infrastructure [34]. Village-level health subcenters, each serving a population of 5,000 (3,000 in tribal, hilly, or inaccessible areas), conduct vitamin A supplementation. Drawing from state subcenter data [40], we estimated subcenter coverage by conservatively assuming each subcenter covers 3,000 people and then dividing the number of people covered by the total state population. Because village-level health subcenters serve only a fraction of the population in each state, we included supplementation costs for all areas currently served by health subcenters [40] as well as the additional costs of supplementing children in areas currently lacking subcenter coverage, which would require additional resources for delivery [22]. The supplementation coverage achievable was adjusted downward according to an estimated rate of health worker absenteeism [41]. Given our assumptions regarding coverage and absenteeism, we found that state coverage ranged from 20 percent in Uttar Pradesh to 61 percent in Himachal Pradesh, with an average of 25 percent. For blindness, we conservatively assumed that the prevalence of corneal xerophthalmia cases is one-tenth the prevalence of Bitot’s spots [24–29], and without treatment, one-half of all corneal cases lead to blindness [16]. Averted morbidity DALYs were calculated as the sum of disability due to Bitot’s spots, night blindness, and blindness multiplied by their respective treatment effectiveness rates. Because data on prevalence rates are scant, other sequelae of xerophthalmia due to VAD, such as corneal xerosis and keratomalacia, are not considered. Consequently, estimates for averted contemporaneous disability are conservative.

### High-dose vitamin A supplementation

We considered a massive dose supplementation program providing semiannual doses of 200,000IU to preschoolers, who are more responsive to high-potency vitamin A supplementation and more susceptible to corneal xerophthalmia [16]. It has been shown that vitamin A supplementation does not benefit early infant survival [30–33]. The current vitamin A supplementation program in India concentrates on children 9 to 36 months [34].

**Table 1. Effectiveness of interventions in reducing VAD burden.**

| Intervention                | Percentage reduction |
|-----------------------------|----------------------|
| Bitot’s spots (children)    | 26–75                |
| Night blindness (children)  | 46–100               |
| Blindness (children)        | 43–75                |
| Mortality (children)        | 4–23                 |

**Table 2. Cost of each intervention.**

| Intervention                        | Cost                        |
|-------------------------------------|-----------------------------|
| **Supplementation**                 |                             |
| Shipping, storage, delivery, and wastage for 2 doses of vitamin A per year | US$0.07 (Rs. 2.58) per child per year [62] |
| Administrative and regulatory costs, training, promotional and educational materials, and program monitoring and evaluation | US$0.08 (3.33Rs) per child per year [63] |
| Total (areas w/subcenters)         | US$0.15 (Rs. 5.91) per child per year |
| Total (areas w/o subcenters)       | US$0.65 (Rs. 26) per child per year [22] |
| **Fortification**                   |                             |
| Cost to fortify 1 kg of oil         | US$0.001 (Rs. 0.045) to US$0.005 (Rs. 0.22) [63,64] |
| Administrative and regulatory costs, training, promotional and educational materials, and program monitoring and evaluation (per kg of oil) | US$0.002 (Rs. 0.062) [63] |
| Bottling costs (per l of oil)      | US$0.09 (Rs. 3.75) [65,66] |
| **GM fortification**                |                             |
| Administrative and regulatory costs, training, promotional and educational materials, and program monitoring and evaluation (per kg of oil) | US$0.002 (Rs. 0.062) [63] |
| Bottling costs (per l of oil)      | US$0.09 (Rs. 3.75) [65,66] |
| One-time regulatory approval cost   | US$5.6 million (22.7 crore Rs.) [66] |
intake of the entire population. Population estimates for new and expectant mothers for a given year are based on age-specific fertility rates and female population numbers from each state.

We calculated morbidity and mortality efficacy based on current vitamin A consumption, improved vitamin A (IVA) intake with fortified mustard oil, and recommended daily allowances (RDA), following methods used by Zimmermann and Qaim [13]. RDA values for preschool children and for new and expectant mothers were estimated to be 400µg and 775µg, respectively [3]. IVA is calculated by adding current vitamin A consumption [3,42] to current mustard oil consumption times a retinol concentration of 18µg/g and a VA retention rate. Retention rates of VA supplement during storage exceed 92 percent after six months [43]. VA supplement has a retention rate of 78-90 percent after brief, low-heat frying, which is how approximately 90 percent of oil consumed is used [43]. Because the supply chain from producer to retailer is fairly efficient, and because rural households typically use mustard oil soon after purchase, we chose a conservative retention rate of 80 percent. Mustard oil consumption among preschoolers is estimated based on average consumption data (kg/month/person/household) [44], state-specific household age structure, and age-specific consumption rates [44,45] and conservatively scaled down based on income and age because the poorest segments of a population tend to consume less mustard oil per person than average [44] and children consume less than adults.

DALYs from averted morbidity and mortality were calculated under the assumption that fortified mustard is available in the same proportion for all consumers, and that for new and expectant mothers the intervention prevents death among a different set of women each year. The costs included the cost for the fortification process itself as well as other costs to prevent vitamin A degradation and ensure product quality, such as bottling and quality control (Table 2). We assumed that all mustard oil consumed is required to be fortified, and we explicitly accounted for administrative and regulatory costs, training, promotional and educational materials, and program monitoring and evaluation. Because vitamin A fortificant degrades readily when exposed to light, the costs of bottling in opaque containers was also considered.

Biofortification with genetically modified mustard. Since GM fortification and industrial fortification are similar delivery strategies for vitamin A, the cost-effectiveness analyses of the two interventions were alike except for parameter adjustments regarding costs and vitamin A content (Table 2). Based on field trials, in which pressed oil from genetically modified mustard seed could contain as much as 600µg per gram of oil, we conservatively assumed that GM-fortified mustard oil has a beta-carotene content of 185µg/g [46], and that only 71 percent of the beta-carotene is retained after cooking [47]. The variety of mustard being developed for expression of beta-carotene accounts for 70-80 percent of the mustard grown in India. Hence, we assume that only 75 percent of the mustard seed that is pressed into oil is GM fortified. Based on these assumptions, we calculated an effective concentration of 49.3µg of vitamin A per g of oil at the consumption level.

Costs related to the distribution, sale, and regulation of GM-fortified oil were assumed to be the same as for industrially fortified oil, since both would require bottling in opaque containers and presumably require similar regulatory, monitoring, and enforcement frameworks. However, there are no costs related to adding artificial fortificant, since beta-carotene would occur naturally in GM-fortified mustard seeds and the cold-pressed oil produced from it. Instead, we incorporated a one-time fixed cost of US$3.6 million (Rs. 22.7 crore) to account for the costs of licensing on the assumption that the R&D has already been completed and the regulatory mechanisms for licensing such products are already in place. We apportioned this amount among the states considered in this analysis according to their total rural population size and applied the same rate to urban populations. We estimated that these fixed costs would amount to approximately US$0.01 (Rs. 0.40) per person.

To prevent the escape of engineered genetic material into natural ecosystems, the growing of genetically modified mustard on a commercial scale could require bioconfinement practices by farmers, as well as additional regulatory and monitoring activities [48]. However, cost estimates for regulation of transgenic crops in India do not yet exist because the policies themselves are still being formulated, and there is a great deal of regulatory ambiguity regarding transgenic crops. The most comparable example is Bt cotton, which in 2002 became the first transgenic crop approved for cultivation in India [49]. Farmers and others involved in cotton production do not yet incur additional costs for producing Bt cotton other than a premium for the purchase of transgenic seeds. Since GM-fortified mustard is not expected to be sold at an additional premium and because the regulatory framework is still unclear, we ignored any additional costs of growing GM-fortified versus regular mustard.

Sensitivity analysis

Because of the uncertainty surrounding our assumed parameters, we used a Monte Carlo sampling method to evaluate the robustness of our results [50]. We found that our assumed mortality range had a significant effect on the results. To more accurately depict the range over which our results varied, we adjusted the analysis to examine an optimistic scenario and a conservative scenario. In the optimistic scenario we assumed a mortality reduction rate of 23 percent, and in the conservative scenario we assumed a mortality reduction rate of 4 percent. All other parameters were varied over their full range to produce confidence intervals around our different scenarios (see the Supplementary Notes S2 for detailed information on sensitivity analysis and Table S1 for parameter ranges).

Results

Our analysis estimated the effectiveness in reducing morbidity and mortality associated with vitamin A deficiency through three methods: supplementation for 1- to 4-year-olds, industrial fortification of mustard oil, and GM fortification of mustard seed. Each scenario was evaluated using a conservative efficacy rate (4 percent) and an optimistic efficacy rate (23 percent) of averted mortality, and results were obtained for the number of DALYs and deaths averted over a 20-year time frame. The costs of each intervention are presented in Table 3, and the incremental cost-effectiveness of each non-dominated intervention in $/DALY and $/Death Averted are presented in Tables 4 and 5, respectively.

Table 3. Cost of intervention implementation.

| Intervention            | Cost US$(millions) |
|-------------------------|--------------------|
| Supplementation         | 637 (607–667)      |
| areas w/subcenters       | 36 (35–38)         |
| areas w/o subcenters     | 600 (570–630)      |
| Fortification            | 3,177 (3,099–3,255) |
| GM fortification         | 3,103 (3,028–3,179) |

Note: parentheses denote 95 percent confidence intervals.

doi:10.1371/journal.pone.0012046.0003
The ICER of moving from one intervention to a more expensive alternative is the difference in cost divided by the difference in DALYs or deaths averted associated with each intervention. We also calculated an internal rate of return for each intervention in Table 6, though these are not incremental.

As shown in Table 4, we estimate that over a 20-year period, GM fortification could avert the most DALYs (18 million–34 million) and deaths (113,000–654,000), but at approximately 5 times the cost of supplementation, which could avert 12 million–28 million DALYs and 105,000–608,000 deaths. The incremental cost of supplementation, evaluated at $23 (95 percent CI: 22–24) to $30 (95 percent CI: 46–54) per DALY averted, is far less than the incremental cost of GM fortification, $403 (95 percent CI: 389–418) to $450 (95 percent CI: 438–461) per DALY averted. A similar relationship occurs when considering only deaths averted (Table 5). However, these results ignore any fixed costs of expanding supplementation services to populations without subcenters. Moreover, supplementation targets only young children and does not alleviate the suffering of pregnant mothers. Industrial fortification averts fewer DALYs and deaths at a greater cost than both GM fortification and supplementation and thus is dominated by both of them. Industrial fortification is strictly dominated by GM fortification because it is assumed to have a lower vitamin A content than GM-fortified oil.

The cost-effectiveness of supplementation varies depending on health subcenter coverage. In areas where health subcenters exist, the cost per DALY averted can be as low as $5 to $11 (or $200 to $1,300 per death averted), whereas additional delivery costs necessary in areas without subcenters result in an incremental cost-effectiveness ratio of $42 to $90 per DALY averted (or $1,900 to $11,100 per death averted). Of the DALYs averted via supplementation, 9.5 million (95 percent CE: 9.2–9.8) to 20.6 million (95 percent CI: 20.3–20.8) occur in areas lacking subcenter coverage, versus 3.2 million (95 percent CE: 3.1–3.3) to 7.1 million (95 percent CE: 7.0–7.2) in areas with existing subcenters. Similarly, the number of avertable deaths is greater, 78,000 (95 percent CI: 75,000–81,000) to 450,000 (95 percent CI: 447,000–453,000), in areas without subcenters than in areas with subcenter coverage, 27,000 (95 percent CI: 26,000–28,000) to 158,000 (95 percent CI: 157,000–158,000).

The cost-effectiveness ratio for expanding supplementation to all areas translates to an internal rate of return of 68–104 percent, which far exceeds the internal rate of return of industrial fortification (6–22 percent) and GM fortification (21–42 percent) (Table 6). The internal rate of return for supplementation in areas where health subcenters are located (142–195 percent) is greater than the IRR in areas without subcenters (59–93 percent), again because of greater delivery costs in those areas.

Estimates for DALYs and deaths averted for each intervention exhibited significant variation among states and between rural and urban areas (see Supplementary Table S2), but overall patterns remained the same as those described above. VAD interventions had higher cost-effectiveness ratios across all interventions in states that had low underlying mortality rates, such as West Bengal and Himachal Pradesh. Interventions also had higher cost-effectiveness ratios in urban areas because of their lower baseline mortality rates.

**Discussion**

Vitamin A supplementation, at US$23–$50 per DALY averted, is much less costly than either fortification intervention. Because of the substantially greater cost for GM fortification, the incremental cost-effectiveness of this intervention is US$405–$450 per DALY averted, though it would reach a wider swath of the population, particularly pregnant mothers. Industrial fortification of mustard oil, which averts fewer DALYs and costs more than either supplementation or GM fortification, is not an attractive option for policymakers under the assumptions we have made about costs and benefits.

Our estimates for the cost-effectiveness of a vitamin A supplementation program targeting preschool children are in line with estimates previously reported in the literature, at least for areas with subcenter coverage [51,52]. However, our cost-effectiveness estimates for people without access to functioning health subcenters, a situation that applies to some 70 percent of

| Table 4. DALYs averted for each intervention over 20-year time horizon. |
|---|
| **Intervention** | **DALYs averted (millions)** | **Incremental cost-effectiveness ($/DALY)** |
| **Low efficacy** | **High efficacy** | **Low efficacy** | **High efficacy** |
| Supplementation | 12.7 (12.4–13.1) | 27.6 (27.3–28.0) | 50 (46–54) | 23 (22–24) |
| Fortification | 10.8 (10.5–11.1) | 18.6 (18.2–19.0) | Dominated | Dominated |
| GM fortification | 18.1 (17.8–18.5) | 33.7 (33.2–34.1) | 450 (438–461) | 403 (389–418) |

Note: Parentheses denote 95 percent confidence intervals. Each intervention is compared with immediately less effective and non-dominated alternative intervention. doi:10.1371/journal.pone.0012046.t004

| Table 5. Deaths averted for each intervention over 20-year time horizon. |
|---|
| **Intervention** | **Deaths averted (thousands)** | **Incremental cost-effectiveness ($/death averted)** |
| **Low efficacy** | **High efficacy** | **Low efficacy** | **High efficacy** |
| Supplementation | 105 (102–109) | 608 (604–611) | 6,100 (5,600–6,600) | 1,000 (1,000–1,100) |
| Fortification | 86 (84–88) | 356 (349–362) | Dominated | Dominated |
| GM fortification | 113 (110–116) | 654 (647–660) | 303,300 (310,000–297,100) | 53,000 (48,700–57,900) |

Note: Parentheses denote 95 percent confidence intervals. Each intervention is compared with immediately less effective and non-dominated alternative intervention. doi:10.1371/journal.pone.0012046.t005
the population, are higher than these previous estimates. The difference may be due to the numerous assumptions in our analysis intended to err on the conservative side of avertable disease burden, as well as uncertainties about the cost of supplementation. In particular, despite recent evidence that VAD supplementation is effective in significantly reducing morbidity [36], our lack of data on existing levels of supplementation required us to apply conservative effectiveness rates, since the incremental effectiveness on existing levels of supplementation required us to apply any underlying level of supplementation greater than zero.

In particular, despite recent evidence that VAD supplementation is effective in significantly reducing morbidity [36], our lack of data on existing levels of supplementation required us to apply conservative effectiveness rates, since the incremental effectiveness on existing levels of supplementation required us to apply any underlying level of supplementation greater than zero.

Based on the few formal cost-effectiveness studies of vitamin A fortification comparable to ours, fortifying oil in India may be more costly than interventions in other countries that use different vitamin A delivery vectors. For example, in Central America the annual cost of sugar fortification has been estimated at around US$1 per high-risk person reached (i.e., young children and women of childbearing age) [53,54], and a study of wheat fortification in the Philippines indicated an annual cost of $1.3 to $2.3 per child with inadequate vitamin A intake [55]. These reported costs are less than our estimate for fortification of approximately $1.50 per year per person at risk (i.e., pregnant women and children). Such differences may be at least partly related to India’s large number of small, disaggregated mustard oil producers—in contrast to the concentrated manufacture of fortification vehicles evaluated in other studies—and the consequent additional difficulty and cost of ensuring that the oil is fortified.

Other analyses of GM fortification have tended to find that introducing biofortified products may be less costly than our estimates for GM mustard. In an *ex ante* analysis of golden rice in the Philippines, Zimmerman and Qaim [13] estimated that introducing GM-fortified rice would result in a gain of 204,000–1,382,000 DALYs per annum, which is similar to our calculation for GM mustard. However, they estimated that the total costs for introducing Golden Rice in India, including development, breeding, regulation, dissemination, marketing, and maintenance efforts, would amount to only $16.5 million–$21.5 million over 20 years. Using the same framework, Meenakshi and colleagues [18] evaluated the prospective introduction of a number of GM-fortified crops into several countries and also found generally lower costs and less effectiveness, though the range was great.

In contrast to our finding that supplementation was more cost-effective than fortification, other studies comparing alternative vitamin A interventions have found that fortification can be the more attractive option [53,55,56]. However, these studies generally acknowledged that supplementation is more appropriate in settings where the fortified food product is not consumed in sufficient amounts. Furthermore, although GM fortification may have a lower cost-effectiveness ratio than supplementation in some cases, it may not deliver adequate amounts of vitamin A and may be insufficient as a stand-alone strategy [11]. Hence, the optimal decision depends on the consumption patterns of the fortified food, and the two strategies can be complementary. For instance, even though our results suggest that supplementation has a substantially lower cost-effectiveness ratio, implementation of a universal supplementation program in India has been problematic. After 30 years, the National Prophylaxis Programme for Prevention of Blindness has achieved coverage of only about 30 percent [6,17,22], and controversy over its implementation and effectiveness [57] has further complicated progress.

GM fortification, on the other hand, offers some advantages over supplementation even if the incremental cost-effectiveness ratio is large. Unlike periodic supplementation, GM fortification would provide a continual source of vitamin A and is thus more likely to result in a sustained rise in serum retinol levels [27,58], providing sustained protection from anemia and infectious disease. Additionally, our analysis shows that GM fortification of mustard oil might avert a substantially greater disease burden than supplementation alone, mostly because it would benefit the entire population, rather than a single targeted age group. Also, seed production and distribution in India are relatively centralized, facilitating implementation and enforcement. However, GM fortification faces some challenges. Although mustard oil is a good vehicle for supplying beta-carotene in states where mustard oil is widely consumed, people in many parts of the country do not consume mustard oil.

Introduction of GM fortified seed may also face acceptance hurdles. Our discussions with farmers suggest that although the introduction of GM-fortified seed would be readily accepted, the color of the resulting oil may face some resistance from consumers, necessitating additional costs for education and awareness campaigns. There also may be regulatory hurdles to widespread use of GM technologies.

In summary, our analysis suggests that vitamin A supplementation is a less costly method of improving the vitamin A status of vulnerable populations in India but would avert fewer DALYs and deaths than fortification via genetically recombinant mustard oil. GM mustard could reduce VAD disease burden by a substantially greater degree because of its potentially wider reach. However, our analysis does not include the fixed costs associated with expanding supplementation in areas currently without subcenter coverage. Our results can help inform the selection of VAD reduction strategies at the state level. They indicate that GM fortification of mustard oil could be used to reach vulnerable populations, especially those that do not readily benefit from supplementation
programs, such as mothers and populations without access to Primary Health Care facilities. The optimal approach to addressing VAD in India thus will likely include a mix of strategies, given their relative advantages and disadvantages and the cultural and socioeconomic variations that exist across India. In mustard-consuming states at least, GM fortification of mustard oil has the potential to substantially reduce VAD. States that do not consume mustard oil, however, must continue to rely on supplementation to improve their VA status or develop alternative fortification vehicles.

**Supporting Information**

**Notes S1** Mustard oil consumption in India. Found at: doi:10.1371/journal.pone.0012046.s001 (0.03 MB DOC)

**Notes S2** Sensitivity analysis. Found at: doi:10.1371/journal.pone.0012046.s002 (0.04 MB DOC)

**Figure S1** Total domestic consumption of edible oil, 1972–2006, by type. Note: Consumption for 2006 is an estimate. Source: United States Department of Agriculture 2006. Found at: doi:10.1371/journal.pone.0012046.s003 (0.41 MB TIF)

**Figure S2** Monthly per capita purchases of mustard oil by household income in rural and urban households of Rajasthan, Uttar Pradesh, Bihar, and Madhya Pradesh, 2005. Source: IMRB International (2006). Found at: doi:10.1371/journal.pone.0012046.s004 (2.84 MB TIF)

**Table S1** Parameter values for sensitivity analysis. Found at: doi:10.1371/journal.pone.0012046.s005 (0.11 MB DOC)

**Table S2** State-specific cost-effectiveness calculations ($/DALY averted). Found at: doi:10.1371/journal.pone.0012046.s006 (0.05 MB DOC)

**Acknowledgments**

Paula Whitacre, Saraswathi Bulusu, Vibha Dhawan, Cherian George, Rajan Kapoor, Anand Lakshman, Rakesh Mittal, S.R. Rao, H.B. Singh, and Satyajeet Yadav provided substantive and valuable input to the report.

**Author Contributions**

Conceived and designed the experiments: JC EYK RL. Analyzed the data: JC EYK RL. Wrote the paper: JC EYK RL.

**References**

1. West Jr. K (2002) Extent of vitamin A deficiency among preschool children and women of reproductive age. Journal of Nutrition 132: 2387–2386.
2. Kapil U (2001) National consultation on benefits and safety of administration of vitamin A to pre-school children and pregnant and lactating women. Indian Pediatrics 38: 37–42.
3. Toteja G, Singh P (2004) Micronutrient Profile of Indian Population. New Delhi: Indian Council of Medical Research.
4. Mason J, Bales A, Beda-Andourou M, Copeland N, Curris T, et al. (2005) Recent trends in malnutrition in developing regions: vitamin A deficiency, anemia, iodine deficiency, and child underweight. Food and Nutrition Bulletin 26: 59–101.
5. NNMB (2003) Prevalence of Micronutrient Deficiencies. NNMB Technical Report No. 22.
6. IIPS (2000) National Family Health Survey (NFHS-2), 1998–99: India. Mumbai: International Institute for Population Sciences.
7. Christian P (2002) Recommendations for indicators: night blindness during pregnancy—a simple tool to assess vitamin A deficiency in a population. Journal of Nutrition 132: 2884–2888.
8. Sommer A, West KP (1996) Vitamin A Deficiency: Health, Survival, and Vision. New York: Oxford University Press.
9. Paine JA, Shipton CA, Chagger S, Howell RM, Kennedy MJ, et al. (2005) Improving the nutritional value of Golden Rice through increased pro-vitamin A content. Nat Biotech 23: 482–487.
10. Stein AJ, Sachdev HPS, Quam M (2006) Potential impact and cost-effectiveness of Golden Rice. Nat Biotech 24: 1200–1201.
11. Dawe D, Robertson R, Unnevehr L (2002) Golden Rice: what role could it play in alleviation of vitamin A deficiency? Food Policy 27: 541–560.
12. Egana NE (2003) Vitamin A deficiency and Golden Rice—a literature review. Journal of Nutritional & Environmental Medicine 13: 169–184.
13. Zimmerman R, Quam M (2006) Potential health benefits of Golden Rice: a Philippine case study. Food Policy 29: 147–168.
14. Agricultural Biotechnology Support Project (2003) Final Technical Report. East Philippine Case Study. Food Policy 29: 147–168.
15. Shesmaker CK, Sherley JA, Daley M, Colburn S, Ke DY (1999) Seed-specific overexpression of phytoene synthase: increase in carotenoids and other metabolic effects. Plant Journal 20: 401–412.
16. West Jr K, Darnon-Hill I (2001) Vitamin A deficiency. In: Sembra RD, Blohm MW, eds. Nutrition and Health in Developing Countries. Tokyo, NJ: Humana Press pp. 257–306.
17. Micronutrient Initiative (2005) Controlling Vitamin & Mineral Deficiencies in India: Meeting the Goal. New Delhi: Micronutrient Initiative.
18. Menushaki JV, Johnson N, Mamyong VM, Groote HD, Javelosa J, et al. (2007) How cost-effective is biofortification in combating micronutrient malnutrition? An ex-ante assessment. Washington, DC: HarvestPlus Working Paper No.2.
19. Stein AJ, Sachdev HPS, Quam M (2008) Genetic engineering for the poor: Golden Rice as public health in India. World Development 36: 144–150.
20. Rushby JAF, Hansou K (2001) Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy and Planning 16: 326–331.
21. World Bank (1993) World Development Report: Investing in Health. Washington, DC: International Bank for Reconstruction and Development.
22. Lakshman A (2006) National Programme Office for Vitamin A Supplementation, Micronutrient Initiative. Personal communication to Jeffrey Chow, 30 June.
23. Chandigarh National Informatics Centre (2007) Chandigarh in figures: economic indicators-2005. http://chandigarh.gov.in/knowchd_stat.htm (accessed: March 13, 2007).
24. Cohen N, Rahman H, Mitra M, Sprague J, Islam S, et al. (1987) Impact of massive doses of vitamin A on nutritional blindness in Bangladesh. American Journal of Clinical Nutrition 45: 970–976.
25. Rahmatullah L, Underwood B, Thulasiraj R, Milton R, Ramaswamy K, et al. (1990) Reduced mortality among children in southern India receiving a small weekly dose of vitamin A. New England Journal of Medicine 325: 929–933.
26. Rao BRH, Klotz CE, Benjamin Y, Rao PSS, Begum A, et al. (1961) Nutrition and health status survey of school children. Indian Journal of Pediatrics 28: 39–50.
27. Solon FS, Fernandez TL, Latham MC, Popkin BM (1979) An evaluation of strategies to control vitamin A deficiency in the Philippines. American Journal of Clinical Nutrition 32: 1445–1453.
28. Swami H, Thakur J, Bhata S (2002) Mass supplementation of vitamin A linked to National Immunization Day. Indian Journal of Pediatrics 69: 675–678.
29. Swaminathan M, Souheila T, Thummayamma B (1976) Field prophylactic trial with a single annual oral massive dose of vitamin A. American Journal of Clinical Nutrition 23: 119–122.
30. Daulaire N, Starbeck E, Houston R, Church M, Stukel T, et al. (1992) Childhood mortality after a high dose of vitamin A in a high risk population. BMJ 304: 207–210.
31. Katz J, West KP, Khatri SK, Pahade EK, LeClerq SC, et al. (2000) Maternal low-dose vitamin A or 6-carotene supplementation has no effect on fetal loss and early infant mortality: a randomized cluster trial in Nepal. American Journal of Clinical Nutrition 71: 1570–1576.
32. West Jr. K, Katz J, Shrestha S, LeClerq S, Khatry S, et al. (1995) Mortality of infants <6 mo of age supplemented with vitamin A: a randomized, double-masked trial in Nepal. American Journal of Clinical Nutrition 62: 143–147.
33. WHO/CHD Immunisation-Linked Vitamin A Supplementation Study Group (1998) Randomised trial to assess benefits and safety of vitamin A supplementation linked to immunisation in early infancy. Lancet 352: 1257–1263.
34. Indian Council of Medical Research (2004) Recommendation of National Workshop on Micronutrients Held on 24–25th November, 2003 at Delhi and Organized by Indian Council of Medical Research on behalf of Ministry of Health and Family Welfare. New Delhi: Government of India, Ministry of Health and Family Welfare, Department of Family Welfare, CH Section. No.Z.28020/50/2003-CH.
35. Bhutta Z, Ahmed T, Black R, Cousens S, Lwanga S, et al. (2005) What works? Interventions for maternal and child undernutrition and survival. Lancet 367: 417–440.
37. Herrera MG, Nestel P, El Amin A, Fawzi WW, Mohamed KA, et al. (1992) Vitamin A supplementation and child survival. Lancet 339: 267–271.
38. Vijayaraghavan K, Radiahih G, Prakash BS, Sarma KV, Reddy V (1990) Effect of massive dose vitamin A on morbidity and mortality in Indian children. Lancet 336: 1342–1345.
39. Awasthi S, Peti R, Read S, Bundy D (2007) Six-monthly vitamin A from 1 to 6 years of age DEVTA: Cluster-randomised trial in 1 million children in North India, 2007-04-17, Istanbul.
40. NRHM (2006) Annual Report 2005–2006. New Delhi: National Rural Health Mission, Ministry of Health and Family Welfare, Government of India.
41. Chaudhury N, Hammer J, Kremer M, Murailtharam K, Rogers F (2006) Missing in action: teacher and health worker absence in developing countries. Journal of Economic Perspectives 20: 91–116.
42. NNMB (2006) Diet and nutritional status of rural population. Hyderabad: National Institute of Nutrition.
43. Nicholas Piramal India Limited (2006) Human nutrition & health—fortification. http://www.vfcdnicholas.com/hnh/fortification6.htm (accessed: November 15, 2006).
44. NNMB (1999) Report of Second Repeat Survey—Rural. Hyderabad: National Nutrition Monitoring Bureau.
45. NSS (2001) NSS 55th Round. New Delhi: National Sample Survey Organisation Ministry of Statistics & Programme Implementation Government of India.
46. TERI (2006) Vitamin A socioeconomic review. New Delhi: Tata Energy Research Institute.
47. Manorama R, Rukmini C (1991) Effect of processing on β-carotene retention in crude palm oil and its products. Food Chemistry 42: 253–264.
48. National Research Council (2004) Biological Confinement of Genetically Engineered Organisms. Washington, DC: National Academies Press.
49. Barwale RB, Gadwal VR, Zehr U, Zehr B (2004) Prospects for B cotton technology in India. Journal of Agrobiotechnology Management & Economics 7: 23–26.
50. McKay MD, Beckman RJ, Conover WJ (1979) A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics 21: 239–245.
51. Caulfield L, Richards S, Rivera J, Musgrove P, Black R (2006) Stunting, wasting, and micronutrient deficiency disorders. In: Jamison D, Alleyne G, Breman J, Claeson M, Evans D, et al. (2006) Disease Control Priorities in Developing Countries, 2nd edition. Washington, DC: United States National Institutes of Health.
52. Houston R (2003) Why They Work: An Analysis of Three Successful Public Health Interventions. MOST (USAID Micronutrient Program).
53. Phillips M, Sanghi T, Suárez R, McGinley J, Fiedler J (1996) The costs and effectiveness of three vitamin A interventions in Guatemala. Social Science and Medicine 42: 1661–1668.
54. Mora JO, Dary O, Chinchilla D, Arroyave G (2000) Vitamin A Sugar Fortification in Central America: Experience and Lessons Learned. MOST (USAID Micronutrient Program).
55. Fiedler J, Dazo D, Maqaland H, Juan N, Capistrano M, et al. (2000) Cost analysis as a vitamin A program design and evaluation tool: a case study of the Philippines. Social Science and Medicine 51: 223–242.
56. Dary O (1997) Sugar fortification with vitamin A: a Central American contribution to the developing world. Food Fortification to End Micronutrient Malnutrition: State of the Art Satellite Conference of the XVIIth International Congress of Nutrition, Symposium Report. Ottawa: Micronutrient Initiative.
57. Vijayaraghavan K (2006) Micronutrient Policies and Programs in India: Vitamin A Deficiency Situational Assessment to Guide USAID Investments. NIN.
58. Arroyave G, LA M, JR A (1981) The effect of vitamin A fortification of sugar on the serum vitamin A levels of preschool Guatemalan children: a longitudinal evaluation. American Journal of Clinical Nutrition 34: 41–49.
59. Toteja G, Singh P, et al. (2001) Micronutrient deficiency disorders in 16 districts of India. Part 1 Report of an ICMR task force study-District Nutrition Program. New Delhi: Indian Council of Medical Research.
60. National Institute of Nutrition (NIN) (2001) Annual Report. Hyderabad: National Institution of Nutrition.
61. Chakravarty I, Ghosh K (2000) Micronutrient malnutrition—present status and future remedies. Journal of the Indian Medical Association 98(9): 539–42.
62. Anand K, Sankar R, Kapoor SK, Pandav CS (2004) Cost of syrup versus capsule form of vitamin A supplementation. Indian Pediatrics 41: 377–383.
63. Micronutrient Initiative (MI) (2006) India Micronutrient National Investment Plan 2007–2011. New Delhi: Micronutrient Initiative.
64. Nicholas Piramal India Ltd., Vitamins and Fine Chemicals Division (2006) Pamphlet. Nicorich Oil: Vitamin A for Oil Fortification.
65. Bhushan C (2006) Bottled loot: the structure and economics of the Indian bottled water industry. Frontline 23(7): http://www.hindustanet.com/fine/t2307/stories/20060421006762300.htm (accessed: November 15, 2006).
66. George C (2005) Technical Director, Monsanto. Personal communication to Jeffrey Chow, Eili Klein, and Ramanan Laxminarayan, 2 December.